Clinically relevant genes and regulatory pathways associated with NRAS(Q61) mutations in melanoma through an integrative genomics approach

Therapies such as BRAF inhibitors have become standard treatment for melanoma patients whose tumors harbor activating BRAF(V600) mutations. However, analogous therapies for inhibiting NRAS mutant signaling have not yet been well established. In this study, we performed an integrative analysis of DNA...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Jiang, Wei, Jia, Peilin, Hutchinson, Katherine E., Johnson, Douglas B., Sosman, Jeffrey A., Zhao, Zhongming
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2014
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4385866/
https://ncbi.nlm.nih.gov/pubmed/25537510
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak